The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antidiabetic Biguanides Market Research Report 2025
Synopsis
The global Antidiabetic Biguanides market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antidiabetic Biguanides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic Biguanides.
Report Scope
The Antidiabetic Biguanides market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic Biguanides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidiabetic Biguanides manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
AstraZeneca
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Metformin IR
Metformin SR
Segment by Application
Hospitals
Clinics
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic Biguanides in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Antidiabetic Biguanides market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antidiabetic Biguanides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic Biguanides.
Report Scope
The Antidiabetic Biguanides market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic Biguanides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidiabetic Biguanides manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
AstraZeneca
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Metformin IR
Metformin SR
Segment by Application
Hospitals
Clinics
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic Biguanides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic Biguanides in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antidiabetic Biguanides Market Overview
1.1 Product Overview and Scope of Antidiabetic Biguanides
1.2 Antidiabetic Biguanides Segment by Type
1.2.1 Global Antidiabetic Biguanides Market Value Comparison by Type (2024-2030)
1.2.2 Metformin IR
1.2.3 Metformin SR
1.3 Antidiabetic Biguanides Segment by Application
1.3.1 Global Antidiabetic Biguanides Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Antidiabetic Biguanides Market Size Estimates and Forecasts
1.4.1 Global Antidiabetic Biguanides Revenue 2019-2030
1.4.2 Global Antidiabetic Biguanides Sales 2019-2030
1.4.3 Global Antidiabetic Biguanides Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antidiabetic Biguanides Market Competition by Manufacturers
2.1 Global Antidiabetic Biguanides Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antidiabetic Biguanides Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antidiabetic Biguanides Average Price by Manufacturers (2019-2024)
2.4 Global Antidiabetic Biguanides Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antidiabetic Biguanides, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antidiabetic Biguanides, Product Type & Application
2.7 Antidiabetic Biguanides Market Competitive Situation and Trends
2.7.1 Antidiabetic Biguanides Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antidiabetic Biguanides Players Market Share by Revenue
2.7.3 Global Antidiabetic Biguanides Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic Biguanides Retrospective Market Scenario by Region
3.1 Global Antidiabetic Biguanides Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antidiabetic Biguanides Global Antidiabetic Biguanides Sales by Region: 2019-2030
3.2.1 Global Antidiabetic Biguanides Sales by Region: 2019-2024
3.2.2 Global Antidiabetic Biguanides Sales by Region: 2025-2030
3.3 Global Antidiabetic Biguanides Global Antidiabetic Biguanides Revenue by Region: 2019-2030
3.3.1 Global Antidiabetic Biguanides Revenue by Region: 2019-2024
3.3.2 Global Antidiabetic Biguanides Revenue by Region: 2025-2030
3.4 North America Antidiabetic Biguanides Market Facts & Figures by Country
3.4.1 North America Antidiabetic Biguanides Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antidiabetic Biguanides Sales by Country (2019-2030)
3.4.3 North America Antidiabetic Biguanides Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antidiabetic Biguanides Market Facts & Figures by Country
3.5.1 Europe Antidiabetic Biguanides Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antidiabetic Biguanides Sales by Country (2019-2030)
3.5.3 Europe Antidiabetic Biguanides Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antidiabetic Biguanides Market Facts & Figures by Country
3.6.1 Asia Pacific Antidiabetic Biguanides Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antidiabetic Biguanides Sales by Country (2019-2030)
3.6.3 Asia Pacific Antidiabetic Biguanides Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antidiabetic Biguanides Market Facts & Figures by Country
3.7.1 Latin America Antidiabetic Biguanides Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antidiabetic Biguanides Sales by Country (2019-2030)
3.7.3 Latin America Antidiabetic Biguanides Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antidiabetic Biguanides Market Facts & Figures by Country
3.8.1 Middle East and Africa Antidiabetic Biguanides Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antidiabetic Biguanides Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antidiabetic Biguanides Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antidiabetic Biguanides Sales by Type (2019-2030)
4.1.1 Global Antidiabetic Biguanides Sales by Type (2019-2024)
4.1.2 Global Antidiabetic Biguanides Sales by Type (2025-2030)
4.1.3 Global Antidiabetic Biguanides Sales Market Share by Type (2019-2030)
4.2 Global Antidiabetic Biguanides Revenue by Type (2019-2030)
4.2.1 Global Antidiabetic Biguanides Revenue by Type (2019-2024)
4.2.2 Global Antidiabetic Biguanides Revenue by Type (2025-2030)
4.2.3 Global Antidiabetic Biguanides Revenue Market Share by Type (2019-2030)
4.3 Global Antidiabetic Biguanides Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antidiabetic Biguanides Sales by Application (2019-2030)
5.1.1 Global Antidiabetic Biguanides Sales by Application (2019-2024)
5.1.2 Global Antidiabetic Biguanides Sales by Application (2025-2030)
5.1.3 Global Antidiabetic Biguanides Sales Market Share by Application (2019-2030)
5.2 Global Antidiabetic Biguanides Revenue by Application (2019-2030)
5.2.1 Global Antidiabetic Biguanides Revenue by Application (2019-2024)
5.2.2 Global Antidiabetic Biguanides Revenue by Application (2025-2030)
5.2.3 Global Antidiabetic Biguanides Revenue Market Share by Application (2019-2030)
5.3 Global Antidiabetic Biguanides Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Antidiabetic Biguanides Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Antidiabetic Biguanides Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Antidiabetic Biguanides Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Merck & Co
6.4.1 Merck & Co Corporation Information
6.4.2 Merck & Co Description and Business Overview
6.4.3 Merck & Co Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck & Co Antidiabetic Biguanides Product Portfolio
6.4.5 Merck & Co Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eli Lilly Antidiabetic Biguanides Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sanofi Antidiabetic Biguanides Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Takeda Pharmaceuticals
6.6.1 Takeda Pharmaceuticals Corporation Information
6.6.2 Takeda Pharmaceuticals Description and Business Overview
6.6.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio
6.7.5 Takeda Pharmaceuticals Recent Developments/Updates
6.8 Novo Nordisk
6.8.1 Novo Nordisk Corporation Information
6.8.2 Novo Nordisk Description and Business Overview
6.8.3 Novo Nordisk Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Novo Nordisk Antidiabetic Biguanides Product Portfolio
6.8.5 Novo Nordisk Recent Developments/Updates
6.9 Servier Laboratories
6.9.1 Servier Laboratories Corporation Information
6.9.2 Servier Laboratories Description and Business Overview
6.9.3 Servier Laboratories Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Servier Laboratories Antidiabetic Biguanides Product Portfolio
6.9.5 Servier Laboratories Recent Developments/Updates
6.10 Boehringer Ingelheim
6.10.1 Boehringer Ingelheim Corporation Information
6.10.2 Boehringer Ingelheim Description and Business Overview
6.10.3 Boehringer Ingelheim Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio
6.10.5 Boehringer Ingelheim Recent Developments/Updates
6.11 Bristol-Myers Squibb
6.11.1 Bristol-Myers Squibb Corporation Information
6.11.2 Bristol-Myers Squibb Antidiabetic Biguanides Description and Business Overview
6.11.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio
6.11.5 Bristol-Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antidiabetic Biguanides Industry Chain Analysis
7.2 Antidiabetic Biguanides Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antidiabetic Biguanides Production Mode & Process
7.4 Antidiabetic Biguanides Sales and Marketing
7.4.1 Antidiabetic Biguanides Sales Channels
7.4.2 Antidiabetic Biguanides Distributors
7.5 Antidiabetic Biguanides Customers
8 Antidiabetic Biguanides Market Dynamics
8.1 Antidiabetic Biguanides Industry Trends
8.2 Antidiabetic Biguanides Market Drivers
8.3 Antidiabetic Biguanides Market Challenges
8.4 Antidiabetic Biguanides Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
